TALAPRO-2: part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC)

Authors
Category Primary study
ConferenceASCO Annual Meeting I. Journal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: b4aafe72749999360817ad9235713e1c3f50b9c9
First added on: Dec 20, 2022